Follicle-stimulating hormone inhibits apoptosis in ovarian cancer cells by regulating the OCT4 stem cell signaling pathway

International Journal of Oncology

Volumn 43, Issue 4, 2013, Pages 1194-1204

  Zhang, Zhenbo ^a   Zhu, Yaping ^a   Lai, Yunli ^b   Wu, Xiaomei ^a   Feng, Zhengzhong ^c   Yu, Yinhua ^d,e   Bast Jr, Robert C ^d   Wan, Xiaoping ^a   Xi, Xiaowei ^a   Feng, Youji ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

^c SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^d UNIVERSITY OF TEXAS   (United States)

^e OBSTETRICS AND GYNECOLOGY HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

Apoptosis; Follicle stimulating hormone; OCT4; Ovarian epithelial tumor

Indexed keywords

FOLLITROPIN; NOTCH RECEPTOR; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER STEM CELL; CANCER TISSUE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CYSTADENOCARCINOMA; CYSTADENOMA; EPITHELIUM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOLECULE; OVARIAN CANCER CELL; OVARIAN EPITHELIAL CANCER; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

APOPTOSIS; CARCINOGENESIS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; FOLLICLE STIMULATING HORMONE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OCTAMER TRANSCRIPTION FACTOR-3; OVARIAN NEOPLASMS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; SOXB1 TRANSCRIPTION FACTORS; STEM CELLS;

EID: 84882301671     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2054     Document Type: Article

References (36)

1. Huang Y, Jin H, Liu Y, et al: FSH inhibits ovarian cancer cell apoptosis by up-regulating survivin and down-regulating PDCD6 and DR5. Endocr Relat Cancer 18: 13-26, 2010.
2. Gu G, Yuan J, Wills M and Kasper S: Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 67: 4807-4815, 2007.
3. Karoubi G, Gugger M, Schmid R and Dutly A: OCT4 expression in human non-small cell lung cancer: implications for therapeutic intervention. Interact Cardiovasc Thorac Surg 8: 393-397, 2009.
4. Atlasi Y, Mowla SJ, Ziaee SA and Bahrami AR: OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. Int J Cancer 120: 1598-1602, 2007.
5. Ezeh UI, Turek PJ, Reijo RA and Clark AT: Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer 104: 2255-2265, 2005.
6. Shin S, Mitalipova M, Noggle S, et al: Long-term proliferation of human embryonic stem cell-derived neuroepithelial cells using defined adherent culture conditions. Stem Cells 24: 125-138, 2006.
7. Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK and Trosko JE: Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 26: 495-502, 2005.
8. Zhang S, Balch C, Chan MW, et al: Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68: 4311-4320, 2008.
9. Chiou SH, Wang ML, Chou YT, et al: Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res 70: 10433-10444, 2010.
10. Hu T, Liu S, Breiter DR, Wang F, Tang Y and Sun S: Octamer 4 small interfering RNA results in cancer stem cell-like cell apoptosis. Cancer Res 68: 6533-6540, 2008.
11. Asselin-Labat ML, Vaillant F, Sheridan JM, et al: Control of mammary stem cell function by steroid hormone signalling. Nature 465: 798-802, 2010.
12. Joshi PA, Jackson HW, Beristain AG, et al: Progesterone induces adult mammary stem cell expansion. Nature 465: 803-807, 2010.
13. Hu L, McArthur C and Jaffe RB: Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer 102: 1276-1283, 2010.
14. Baba T, Convery PA, Matsumura N, et al: Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 28: 209-218, 2009.
15. Ferrandina G, Bonanno G, Pierelli L, et al: Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer 18: 506-514, 2008.
16. Curley MD, Therrien VA, Cummings CL, et al: CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 27: 2875-2883, 2009.
17. Alvero AB, Chen R, Fu HH, et al: Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 8: 158-166, 2009.
18. Dou J, Jiang C, Wang J, et al: Using ABCG2-molecule-expressing side population cells to identify cancer stem-like cells in a human ovarian cell line. Cell Biol Int 35: 227-234, 2011.
19. Gao Q, Geng L, Kvalheim G, Gaudernack G and Suo Z: Identification of cancer stem-like side population cells in ovarian cancer cell line OVCAR-3. Ultrastruct Pathol 33: 175-181, 2009.
20. Chen X, Zhang Z, Feng Y, et al: Aberrant survivin expression in endometrial hyperplasia: another mechanism of progestin resistance. Mod Pathol 22: 699-708, 2009.
21. Ji Q, Liu PI, Chen PK and Aoyama C: Follicle stimulating hormone-induced growth promotion and gene expression profiles on ovarian surface epithelial cells. Int J Cancer 112: 803-814, 2004.
22. Zhang Z, Jia L, Feng Y and Zheng W: Overexpression of follicle stimulating hormone receptor facilitates the development of ovarian epithelial cancer. Cancer Lett 278: 56-64, 2009.
23. Liu D, Zhou P, Zhang L, Wu G, Zheng Y and He F: Differential expression of Oct4 in HPV-positive and HPV-negative cervical cancer cells is not regulated by DNA methyltransferase 3A. Tumour Biol 32: 941-950, 2011.
24. Iki K and Pour PM: Expression of Oct4, a stem cell marker, in the hamster pancreatic cancer model. Pancreatology 6: 406-413, 2006.
25. Wang XQ, Ongkeko WM, Chen L, et al: Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology 52: 528-539, 2010.
26. Venn A, Watson L, Bruinsma F, Giles G and Healy D: Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 354: 1586-1590, 1999.
27. Brekelmans CT: Risk factors and risk reduction of breast and ovarian cancer. Curr Opin Obstet Gynecol 15: 63-68, 2003.
28. Tavani A, Ricci E, La Vecchia C, et al: Influence of menstrual and reproductive factors on ovarian cancer risk in women with and without family history of breast or ovarian cancer. Int J Epidemiol 29: 799-802, 2000.
29. Riman T, Persson I and Nilsson S: Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. Clin Endocrinol (Oxf) 49: 695-707, 1998.
30. Li Y, Ganta S, Cheng C, Craig R, Ganta RR and Freeman LC: FSH stimulates ovarian cancer cell growth by action on growth factor variant receptor. Mol Cell Endocrinol 267: 26-37, 2007.
31. Lau MT, Wong AS and Leung PC: Gonadotropins induce tumor cell migration and invasion by increasing cyclooxygenases expression and prostaglandin E(2) production in human ovarian cancer cells. Endocrinology 151: 2985-2993, 2010.
32. Choi JH, Choi KC, Auersperg N and Leung PC: Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells. Cancer Res 66: 3912-3920, 2006.
33. Xu H, Wang W, Li C, et al: WWP2 promotes degradation of transcription factor OCT4 in human embryonic stem cells. Cell Res 19: 561-573, 2009.
34. Chen T, Du J and Lu G: Cell growth arrest and apoptosis induced by Oct4 or Nanog knockdown in mouse embryonic stem cells: a possible role of Trp53. Mol Biol Rep 39: 1855-1861, 2012.
35. Qian X, Xi X and Li L: Nuclear survivin is associated with malignant potential in epithelial ovarian carcinoma. Appl Immunohistochem Mol Morphol 19: 126-132, 2011.
36. Zhang Z, Liao H, Chen X, et al: Luteinizing hormone upregulates survivin and inhibits apoptosis in ovarian epithelial tumors. Eur J Obstet Gynecol Reprod Biol 155: 69-74, 2010.